Navigating Healthcare Policy 2025 | Part Two: Executive Priorities and Implications for Pharma
The US pharmaceutical industry is grappling with changes brought on by the health policy priorities of President Trump’s administration, which has laid out a strategy to reduce drug prices, re-shore pharmaceutical manufacturing, and overhaul federal healthcare programs. The impact of these policies is amplified by the administration’s realignment of federal healthcare agencies under a unified “Make America Healthy Again” vision. In this second installment of a two-part series, we explore how through a combination of executive actions, legislative reforms, and sweeping agency leadership changes, the Trump Administration is reshaping how drugs are approved, priced, manufactured, and reimbursed. (October 2025)
Download the White Paper
"*" indicates required fields